- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02004886
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
August 7, 2018 updated by: Merck Sharp & Dohme LLC
A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus
This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus.
The primary hypothesis is that MK-0893 will reduce 24-hour weighted mean glucose (WMG) significantly more than placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
74
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 2 diabetes
- Not currently on antihyperglycemic agent (AHA) or AHA monotherapy (not to include treatment with insulin or thiazolidinediones [i.e., peroxisome proliferator activated receptor-gamma, PPARγ agents])
- male or a female of non-childbearing potential. Women must be postmenopausal or premenopausal and documented surgically sterilized
- A body mass index (BMI) that is > 20 and ≤ 40 kg/m2
Exclusion Criteria:
- History of type 1 diabetes or assessed by the investigator as possibly having type 1 diabetes
- History of ketoacidosis; clinically unstable or rapidly progressive diabetic retinopathy, nephropathy, neuropathy
- Treatment for diabetes within 3 months of study participation with combination anti-hyperglycemic therapy, insulin or thiazolidinediones (e.g., rosiglitazone or pioglitazone)
- oral corticosteroid medications within 2 weeks prior to study participation, or requires digoxin, warfarin, warfarin-like anticoagulants, theophylline, anti-dysrhythmic or anti-seizure medications, immunosuppressants, or anti-neoplastic agents, or herbal remedies
- History of acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV)
- History of gastrointestinal problems or disorders or extensive bowel or gastric surgery
- History of significant or unstable cardiovascular disease
- History of neoplastic disease
- History of hepatic disease
- History of seizures, epilepsy or other neurologic disease
- History of myelodysplastic or pre-leukemic disorders or other severe hematological disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MK-0893 (40 mg)
MK-0893 40-mg q.d.
(quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
|
10 mg and 100 mg tablets
Placebo tablets matching MK-0893
Placebo tablets matching metformin
|
EXPERIMENTAL: MK-0893 (120 mg)
MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d.
tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
|
10 mg and 100 mg tablets
Placebo tablets matching MK-0893
Placebo tablets matching metformin
|
ACTIVE_COMPARATOR: Metformin (2000 mg)
Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d.
(bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg.
b.i.d. and matching placebo to MK-0893.
|
Placebo tablets matching MK-0893
Placebo tablets matching metformin
500 mg metformin tablets
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Placebo tablets matching the MK-0893 and placebo tablets matching metformin.
|
Placebo tablets matching MK-0893
Placebo tablets matching metformin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4
Time Frame: Baseline and Week 4
|
Blood samples were collected 30 minutes prior to all meals, and 15, 30, 60, 90, 120, 180 minutes post-meal, then and at midnight, 3 AM, and the next morning at 6:30 AM and 7:30 AM.
A 24-hour weighted mean glucose (WMG) was determined by averaging multiple plasma glucose measurements over a 24-hour period.
|
Baseline and Week 4
|
Number of Participants Experiencing an Adverse Event (AE)
Time Frame: Up to 42 days
|
An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.
|
Up to 42 days
|
Number of Participants Discontinuing Study Treatment Due to an AE
Time Frame: Up to 28 days
|
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Fasting Plasma Glucose (FPG)
Time Frame: Baseline and Week 4
|
Plasma Glucose levels were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.
|
Baseline and Week 4
|
Change From Baseline in Fructosamine at Week 4
Time Frame: Baseline and Week 4
|
Fructosamine levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.
|
Baseline and Week 4
|
Change From Baseline in Fasting C-peptide at Week 4
Time Frame: Baseline and Week 4
|
Fasting C-peptide levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.
|
Baseline and Week 4
|
Change From Baseline in Fasting Insulin at Week 4
Time Frame: Baseline and Week 4
|
Fasting insulin levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.
|
Baseline and Week 4
|
Change From Baseline in 2-hour Post-prandial Glucose Excursion at Week 4
Time Frame: Baseline and Week 4
|
2-hour post-prandial glucose excursion is the change in glucose concentration in the blood 2 hours after a meal.
Change from baseline in 2-hour post-prandial glucose excursion at Week 4 is defined as Week 4 minus baseline.
|
Baseline and Week 4
|
Change From Baseline in 3-hour Area Under the Plasma Concentration Versus Time Curve (AUC) for Glucose at Week 4
Time Frame: Baseline and Week 4
|
Blood samples collected for glucose 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal.
AUC is a measure of the amount of drug in the blood over time.
3-hour AUC for Glucose was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.
|
Baseline and Week 4
|
Change From Baseline in 3-hour AUC for C-peptide at Week 4
Time Frame: Baseline and Week 4
|
Blood samples were collected for C-peptide 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal.
AUC is a measure of the amount of drug in the blood over time.
3-hour AUC for C-peptide was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.
|
Baseline and Week 4
|
Change From Baseline in 3-hour Insulin Total AUC at Week 4
Time Frame: Baseline and Week 4
|
Blood samples were collected for insulin 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal.
AUC is a measure of the amount of drug in the blood over time.
3-hour Insulin Total AUC was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.
|
Baseline and Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 11, 2006
Primary Completion (ACTUAL)
February 7, 2007
Study Completion (ACTUAL)
February 7, 2007
Study Registration Dates
First Submitted
December 3, 2013
First Submitted That Met QC Criteria
December 3, 2013
First Posted (ESTIMATE)
December 9, 2013
Study Record Updates
Last Update Posted (ACTUAL)
September 5, 2018
Last Update Submitted That Met QC Criteria
August 7, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0893-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on MK-0893
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Mayo ClinicCompletedAlzheimer's DiseaseUnited States
-
Merck Sharp & Dohme LLCCompletedType 2 Diabetes Mellitus
-
Merck Sharp & Dohme LLCCompletedHypertension | Isolated Systolic Hypertension (ISH)
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedSolid TumorsUnited States, Canada, Switzerland